Edward M Conway

Title: The Innovative Contributions of Edward M Conway

Introduction

Edward M Conway is a notable inventor based in Overijse, Belgium. He has made significant contributions to the field of biotechnology, particularly in understanding the therapeutic uses of thrombomodulin. His work has implications for treating various inflammatory diseases.

Latest Patents

Conway holds a patent titled "Lectin-like domain of thrombomodulin and its therapeutic use." This patent explores the in vivo role of the N-terminal lectin-like domain of thrombomodulin. By utilizing homologous recombination in murine ES cells, he created mutant mice that lack this specific region of thrombomodulin. Phenotypic analysis revealed that these mutant mice respond similarly to their wild-type counterparts following pro-coagulant challenges, indicating that the protein C pathway remains unaffected by the mutation. However, under several inflammatory stimuli, the mutant mice exhibited increased neutrophil extravasation in various organs. It was discovered that leukocyte adhesion could be inhibited by the addition of recombinant lectin-domain, demonstrating that this domain possesses direct anti-inflammatory properties. This finding suggests that the lectin-like domain can be utilized to develop a medicament for treating a range of inflammatory disease processes. Conway's innovative approach has the potential to impact therapeutic strategies significantly.

Career Highlights

Throughout his career, Edward M Conway has worked with esteemed organizations, including the Vlaams Interuniversitair Instituut Voor Biotechnologie and the D. Collen Research Foundation. His research has been pivotal in advancing our understanding of thrombomodulin and its applications in medicine.

Collaborations

One of Conway's notable collaborators is Désiré Collen, with whom he has worked closely in the field of biotechnology. Their partnership has contributed to significant advancements in research and development.

Conclusion

Edward M Conway's contributions to biotechnology, particularly through his patent on thrombomodulin, highlight his innovative spirit and dedication to advancing medical science. His work continues to inspire future research in the treatment of inflammatory diseases.